Numedicus has used drug repurposing to found and help to develop valuable intellectual property around clinical stage developments for various pharmaceutical and biotechnology companies in the following manner:






Rett Syndrome

Phase II


Opiate-induced respiratory Depression

Phase II


Cancer cachexia

Phase II

In addition to these successes, the Company used its discovery engine to identify and develop deep and rich pipeline for a variety of clients, initially for Arachnova Therapeutics Limited, but also for various Drug Delivery Companies (UK and European). Overall, the therapeutic areas in which the Company has made therapeutic switch proposals include a wide range:

  • acute myocardial infarction
  • cachexia
  • diabetic retinopathy
  • Dupuytren’s contracture
  • nausea and vomiting
  • Raynaud’s phenomenon
  • retinal ischaemia
  • female anorgasmia
  • acute lung injury
  • fibromyalgia
  • functional bowel disease
  • stress incontinence
  • cancer fatigue
  • glaucoma
  • hypertrophic scarring
  • leg ulcers
  • neuropathic pain
  • acute rejection of lung xenograft
  • nociceptive pain
  • overactive bladder
  • premature ejaculation
  • pulmonary hypertension
  • reperfusion injury
  • restenosis
  • rosacea
  • scleroderma
  • wound healing

Latest News

Covid-19: Numedicus is pleased to announce, on behalf of its associated company Exvastat, the start of a Phase II trial in severe Covid-19 patients See here for more details